Published in Pharma Law Weekly, July 26th, 2005
The patent, an extant United States patent registered by the company, relates to an improved delivery system for the administration of large-molecule pharmaceuticals, particularly through the oral and nasal membranes.
The patent covers formulations for the delivery of peptidic drugs, vaccines, and hormones and enhances the company's existing drug-delivery patent portfolio.
"As we prepare to launch commercial distribution of Oral-lyn, our proprietary oral insulin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2005-07-26)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.